Simon J. Crabb
University of Southampton
CancerInternal medicineUrologySurgeryOncologyClinical endpointCystectomyChemotherapyCisplatinDiseaseProstate cancerGemcitabineBladder cancerMuscle invasiveIn patientPhases of clinical researchCancer researchClinical trialMedicineBiology
193Publications
30H-index
3,424Citations
Publications 194
Newest
#2A. Reid (The Royal Marsden NHS Foundation Trust)H-Index: 7
Source
#1Simon J. CrabbH-Index: 30
#2Ruth PlummerH-Index: 37
Last. Fay AshbyH-Index: 2
view all 15 authors...
Source
#1Risa L. Wong (Fred Hutchinson Cancer Research Center)H-Index: 1
#2Lorin Ferris (UW: University of Washington)
Last. Ugo De GiorgiH-Index: 55
view all 19 authors...
Background null Fit patients with metastatic urothelial carcinoma (mUC) receive first-line platinum-based combination chemotherapy (fPBC) as standard of care and may receive additional later-line chemotherapy after progression. Our study compares outcomes with subsequent platinum-based chemotherapy (sPBC) versus subsequent non-platinum-based chemotherapy (sNPBC). null Materials and methods null Patients from 27 international centers in the Retrospective International Study of Cancers of the Urot...
Source
#1Mark Linch (UCL: University College London)H-Index: 19
#2Yien Ning Sophia Wong (UCL: University College London)H-Index: 9
Last. Marian Duggan (UCL: University College London)H-Index: 7
view all 29 authors...
Background: Responses to checkpoint inhibitor (CPI) monotherapy in patients with metastatic castration resistant prostate cancer (mCRPC) have been limited. This is likely due to a “cold” tumour immune microenvironment. We hypothesised that patients with mCRPC will be more likely to respond if they have a positive immunogenic signature (ImS+). We report the response/safety for NIVO + IPI in pts with ImS+ mCRPC from cohort 1 of the NEPTUNES study. null Methods: Pts with mCRPC who progressed follow...
Source
#1Maria Teresa Borrello (UEA: University of East Anglia)H-Index: 7
#2Hanae Benelkebir (UEA: University of East Anglia)H-Index: 5
Last. Arasu Ganesan (UEA: University of East Anglia)H-Index: 46
view all 13 authors...
Lysine-specific demethylase 1 (LSD1/KDM1A) oxidatively removes methyl groups from histone proteins, and its aberrant activity has been correlated with cancers including acute myeloid leukemia (AML). We report a novel series of tranylcypromine analogues with a carboxamide at the 4-position of the aryl ring. These compounds, such as 5 a and 5 b with benzyl and phenethylamide substituents, respectively, had potent sub-micromolar IC50 values for the inhibition of LSD1 as well as cell proliferation i...
Source
#1Olivia A Do (UW: University of Washington)H-Index: 1
#2Lorin Ferris (UW: University of Washington)
Last. Evan Y. Yu (UW: University of Washington)H-Index: 46
view all 19 authors...
Abstract Background Optimal chemotherapy for patients who received cisplatin for localized urothelial carcinoma (UC) and develop metastatic disease is unclear. We compared the efficacy of platinum-based (PBC) versus non–platinum-based (NPBC) first-line chemotherapy for metastasis. Patients and Methods Data were collected from the Retrospective International Study of Cancers of the Urothelial Tract (RISC), a database of 3024 patients from 28 international academic centers from 2005 to 2012. Patie...
2 CitationsSource
#1Robert JonesH-Index: 47
#2Amit Bahl (University Hospitals Bristol NHS Foundation Trust)H-Index: 24
Last. Simon J. Crabb (University of Southampton)H-Index: 30
view all 20 authors...
107Background: Saracatinib is an orally-available, highly selective inhibitor of Abl and Src family members. It is an ATP-competitive tyrosine kinase inhibitor. Preclinical data suggested that the ...
Source
#1Risa Liang Wong (Fred Hutchinson Cancer Research Center)
#2Lorin Ferris (UW: University of Washington)
Last. Evan Y. Yu (UW: University of Washington)H-Index: 46
view all 19 authors...
459Background: First-line platinum-based combination chemotherapy (fPBC) is standard of care for fit patients with mUC. Further lines of therapy include immuno-oncology agents, erdafitinib, and enf...
Source
#1Simon J. CrabbH-Index: 30
#2Sarah Danson (Weston Park Hospital)H-Index: 31
Last. Gareth Griffiths (University of Southampton)H-Index: 30
view all 15 authors...
447Background: Pre-clinical data support a hypothesis that DNA methyltransferase inhibition will circumvent cisplatin resistance in various cancers including urothelial carcinoma (UC). SPIRE compri...
Source
#1Bernadett Szabados (QMUL: Queen Mary University of London)H-Index: 7
Last. Thomas Powles (QMUL: Queen Mary University of London)H-Index: 84
view all 19 authors...
Abstract Background There are limited data on toxicity and surgical safety associated with neoadjuvant programmed death ligand 1 (PD-L1) inhibitors prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC). Objective To present a comprehensive safety analysis of the largest neoadjuvant series, with focus on timing and severity of toxicity and surgical complications occurring after neoadjuvant atezolizumab in patients with MIBC enrolled in the ABACUS trial. Design, s...
2 CitationsSource